Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer Nami.

Slides:

Advertisements

Similar presentations

Jeffrey Bradley, MD Journal of Thoracic Oncology

Advertisements

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases Isabelle Thibault, MD, Mikki Campbell,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

ALK FISH and IHC: You Cannot Have One without the Other

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

Influence of Preoperative Radiation Field on Postoperative Leak Rates in Esophageal Cancer Patients after Trimodality Therapy Aditya Juloori, BS, Susan.

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer Max Dahele, MBChB, MSc, David Palma, MD, Frank Lagerwaard, MD, PhD, Ben Slotman,

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Toxicities of Organs at Risk in the Mediastinal and Hilar Regions Following Stereotactic Body Radiotherapy for Centrally Located Lung Tumors Shuichi.

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

Mitotic Inhibitors Journal of Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Salvage Pulmonary Metastasectomy for Local Relapse After Stereotactic Body Radiotherapy Masatsugu Hamaji, MD, PhD, Takamasa Mitsuyoshi, MD, Akihiko Yoshizawa,

Jeffrey Bradley, MD Journal of Thoracic Oncology

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Salvage Lung Resection for Non-small Cell Lung Cancer After Stereotactic Body Radiotherapy in Initially Operable Patients Fengshi Chen, MD, PhD, Yukinori.

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

High Frequency of Radiation Pneumonitis in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Concurrent Radiotherapy and Gemcitabine.

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Combined Analysis of V20, VS5, Pulmonary Fibrosis Score on Baseline Computed Tomography, and Patient Age Improves Prediction of Severe Radiation Pneumonitis.

In This Issue Journal of Thoracic Oncology

International Thymic Malignancies Interest Group: A Way Forward

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

IASLC 6th Latin American Conference on Lung Cancer

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Successful Treatment with Pemetrexed in a Patient with Mucinous Bronchioloalveolar Carcinoma: Long-Term Response Duration with Mild Toxicity Chiyuki.

Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic.

Farhood Farjah, MD, MPH, David R. Flum, MD, MPH, Scott D

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer Nami Ueki, MD, Yukinori Matsuo, MD, PhD, Yosuke Togashi, MD, Takeshi Kubo, MD, Keiko Shibuya, MD, PhD, Yusuke Iizuka, MD, Takashi Mizowaki, MD, PhD, Kaori Togashi, MD, PhD, Michiaki Mishima, MD, PhD, Masahiro Hiraoka, MD, PhD Journal of Thoracic Oncology Volume 10, Issue 1, Pages 116-125 (January 2015) DOI: 10.1097/JTO.0000000000000359 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Cumulative incidence of radiation pneumonitis worse than grade 2 (≥Gr2 RP) (A), and worse than grade 3 (≥ Gr3 RP), (B), are shown in those with ILD (ILD[+]) and those without ILD (ILD[−]).ILD, interstitial lung disease. Journal of Thoracic Oncology 2015 10, 116-125DOI: (10.1097/JTO.0000000000000359) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 CT images of the patients who had significant ILD findings and underwent SBRT for lung cancer situated in left segment 6. Before SBRT (A), and (B), on 5 days after the completion of SBRT when diagnosed as the acute exacerbation of ILD.CT, computed tomography, ILD, interstitial lung disease; SBRT, stereotactic body radiation therapy. Journal of Thoracic Oncology 2015 10, 116-125DOI: (10.1097/JTO.0000000000000359) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 A, Overall survival rate, (B) incidence of disease progression, and (C) incidence of local progression are shown in those with ILD (ILD[+]) and those without ILD (ILD[−]). ILD, interstitial lung disease. Journal of Thoracic Oncology 2015 10, 116-125DOI: (10.1097/JTO.0000000000000359) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions